Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 153 of 6351
-
Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
Disease control OngoingTo determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
Phase 2 • Sponsor: Alain Algazi • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New biologic drug aims to ease joint pain and swelling in Tough-to-Treat psoriatic arthritis
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene therapy takes on deadly brain tumor
Disease control Stopped earlyThis is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector…
Phase 1/2 • Sponsor: Genenta Science • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can an immunotherapy drug keep liver cancer at bay after surgery?
Disease control OngoingThis study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free survival (RFS) compared to placebo in participants with HCC and are at high risk of recurrence after complete resection with no residual of tumour.
Phase 2/3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Inhaled DNA-buster may shield trauma patients from lung failure
Prevention Recruiting nowSevere hypoxemia following trauma may happen in many circumstances (aspiration, ventilation-associated pneumonia, lung contusion...), most of which are not exclusively associated with a direct injury to the lungs. Severe trauma and associated musculoskeletal injuries result in th…
Phase 3 • Sponsor: University Hospital, Strasbourg, France • Aim: Prevention
Last updated Aug 22, 2026 00:00 UTC
-
Can 3D breast imaging spot more dangerous cancers than standard mammograms?
Diagnosis OngoingRandomized trial comparing tomosynthesis plus synthetic 2D Mammography vs Digital Mammography in respect to incidence of advanced cancers (interval and following round) and interval cancers.
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Diagnosis
Last updated Jul 26, 2026 00:00 UTC
-
Triple-Drug attack aims to wipe out blood cancer cells
Disease control OngoingThe purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Double transplant aims to cure diabetes in kids with weak immune systems
Disease control Recruiting nowThis study evaluates the efficacy of sequential transplantation of umbilical cord blood stem cells and islet cells in children with monogenic immunodeficiency type 1 diabetes mellitus. Umbilical cord blood stem cell transplantation will be performed first. Children with stable im…
Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Brain games may hold key to delaying dementia
Prevention OngoingDementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheime…
Phase 3 • Sponsor: University of South Florida • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
New shot every 3 months could slow rare nerve disease
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran subcutaneous (SC) injection once every 3 months (q3M) or the reference …
Phase 3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Blood test aims to outshine ultrasound for liver cancer detection
Diagnosis OngoingThis is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone to ultrasound alone for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
Disease control CompletedThis study enrolls newly diagnosed unfavorable stage II /stage III-IV classical Hodgkin lymphoma patients. All participants receive 2 cycles ABVD induction chemotherapy, then stratified by interim PET-CT Deauville score for differentiated treatment: standard ABVD for DS1-3, AVD p…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Immunotherapy combo aims to wipe out HER2 breast cancer before surgery
Disease control OngoingA phase 2 open-label, randomized, multi-center trial to evaluate the efficacy and safety of neoadjuvant trastuzumab, pertuzumab and weekly paclitaxel (THP) as compared to neoadjuvant trastuzumab, pertuzumab, pembrolizumab and weekly paclitaxel (THP-pembrolizumab), or neoadjuvant …
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Promising combo aims to stall advanced prostate cancer
Disease control OngoingThe purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A blood test for breast cancer? the future of screening may be in your vein
Diagnosis Recruiting nowDetecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. …
Sponsor: Syantra Inc. • Aim: Diagnosis
Last updated Aug 21, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Stopped earlyThe purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.
Phase 2 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Gene therapy aims to stop severe infections in rare immune disorder
Disease control OngoingThis is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation lentiv…
Phase 3 • Sponsor: Fondazione Telethon • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Phase 1/2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New cocktail aims to stall ovarian cancer
Disease control OngoingThis is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and ol…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Which MS treatment strategy preserves the brain better?
Disease control OngoingThe DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study res…
Phase 4 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC